Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
CA 2467802 A1 · Owner: Mckinzie, David Lee · Inventors: Bymaster, Franklin Porter; Mckinzie, David Lee; Yang, Charles Renkin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Selective norepinephrine reuptake inhibitors particularly atomoxetine, reboxetine and 2-alkylthio substituted phenoxyphenyl propylamines are used , for the treatment of cognitive failure including cognitive failure due to , dementia delirium and schizophrenia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 27, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 27, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 27, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.